Mylan Inc. Jan. 18 announced that its subsidiary, Mylan Pharmaceuticals Inc., has received final approval from the Food and Drug Administration for its generic version of Bayer’s Precose (acarbose) 25 mg, 50 mg, and 100 mg tablets.
Precose is a treatment to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes, the Pittsburgh-based company said. The product is available for immediate shipment.
Acarbose tablets had U.S. sales of approximately $23 million for the 12 months ending Sept. 30, 2010, according to IMS Health.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.